Drug
EE30/DRSP (Yasmin, BAY86-5131)
EE30/DRSP (Yasmin, BAY86-5131) is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
No phase data available
Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(3)
Detailed Status
Completed3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Trials by Status
completed3100%
Recent Activity
0 active trials
Showing 3 of 3
completed
Yasmin Post Marketing Surveillance
NCT00923572
completed
Effects of Drospirenone-containing or -Not Containing Combined Oral Contraceptives on General and Sexual Well-being
NCT00988910
completed
Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (Yasmin® or Any Other Oral Contraceptives (OC)
NCT00905684
Clinical Trials (3)
Showing 3 of 3 trials
NCT00923572
Yasmin Post Marketing Surveillance
NCT00988910
Effects of Drospirenone-containing or -Not Containing Combined Oral Contraceptives on General and Sexual Well-being
NCT00905684
Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (Yasmin® or Any Other Oral Contraceptives (OC)
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3